Advertisement

Molecular and Cellular Biochemistry

, Volume 345, Issue 1–2, pp 77–89 | Cite as

Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism

  • Yanling Chen
  • Lei Jiang
  • Feifei She
  • Nanhong Tang
  • Xiaoqian Wang
  • Xiujin Li
  • Shenghua Han
  • Jinhai Zhu
Article

Abstract

Vascular endothelial growth factor-C (VEGF-C) has a well-defined action on neoplastic lymphangiogenesis and angiogenesis through VEGF receptor-3 (VEGFR-3) and VEGFR-2, respectively, which are generally expressed in endothelial cells. The function of the VEGF-C/receptors pathway in tumor cell types is largely unknown. In this study, we examined the expression and role of VEGF-C/receptors in gallbladder cancer (GBC) cells. We examined the expression of VEGF-C in 50 surgical specimens from gallbladder cancer and three human gallbladder cancer cell lines. Both siRNA and neutralizing antibody to deplete the expression of VEGF-C were used to characterize the biological effect of VEGF-C in GBC NOZ cells. Furthermore, we examined the expression of its receptors, VEGFR-3 and VEGFR-2, in three human GBC cell lines. Our results are as follows: The expression of VEGF-C in the invasive marginal portion was significantly higher than the expression in the central portions. All the three GBC cell lines expressed VEGF-C. Treatment of NOZ cells with VEGF-C siRNA or a neutralizing antibody suppressed cell proliferation and invasion. Moreover, all the three GBC cell lines expressed VEGFR3, but only the NOZ cells expressed VEGFR-2 mRNA. Treatment of NOZ cells with a VEGFR-3 neutralizing antibody suppressed cell invasion, but treatment of NOZ cells with a VEGFR-2 neutralizing antibody suppressed cell proliferation and invasion. In conclusion, GBC cells express both VEGF-C and its receptors. VEGF-C may have a role in the progressive growth and invasion of human GBC through an autocrine mechanism.

Keywords

Gallbladder cancer VEGF-C Receptors siRNA Autocrine Proliferation Invasion 

Notes

Acknowledgments

This study was supported by the Key Sci-Tech Research Foundation of Fujian Province in China (No.2009Y0021), and the Key Project of Fujian Medical University in China (No. 09ZD017).

Conflict of interests

None.

References

  1. 1.
    Donohue JH, Stewart AK, Menck HR (1998) The National Cancer Data Base report on carcinoma of the gallbladder, 1989–1995. Cancer 83:2618–2628CrossRefPubMedGoogle Scholar
  2. 2.
    Cubertafond P, Gainant A, Cucchiaro G (1994) Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 219:275–280CrossRefPubMedGoogle Scholar
  3. 3.
    Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH (1996) Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 224:639–646CrossRefPubMedGoogle Scholar
  4. 4.
    Muratore A, Polastri R, Capussotti L (2000) Radical surgery for gallbladder cancer: current options. Eur J Surg Oncol 26:438–443CrossRefPubMedGoogle Scholar
  5. 5.
    Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M (2006) Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24:228–240CrossRefPubMedGoogle Scholar
  6. 6.
    Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y (2003) Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97:457–464CrossRefPubMedGoogle Scholar
  7. 7.
    Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63:1920–1926PubMedGoogle Scholar
  8. 8.
    Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–198CrossRefPubMedGoogle Scholar
  9. 9.
    Jiang L, Chen YL, She FF (2010) Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma. Zhonghua Zhong Liu Za Zhi 32:190–195PubMedGoogle Scholar
  10. 10.
    Achen MG, McColl BK, Stacker SA (2005) Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7:121–127CrossRefPubMedGoogle Scholar
  11. 11.
    Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672–682CrossRefPubMedGoogle Scholar
  12. 12.
    Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898–3911CrossRefPubMedGoogle Scholar
  13. 13.
    Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298PubMedGoogle Scholar
  14. 14.
    Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468–475CrossRefPubMedGoogle Scholar
  15. 15.
    Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D (2003) VEGF receptor expression and signaling in human bladder tumors. Oncogene 22:3361–3370CrossRefPubMedGoogle Scholar
  16. 16.
    Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD (2002) A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62:854–859PubMedGoogle Scholar
  17. 17.
    Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC, Kuo ML (2006) The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9:209–223CrossRefPubMedGoogle Scholar
  18. 18.
    von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B, Rosewicz S (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119:1358–1372CrossRefGoogle Scholar
  19. 19.
    Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506–516CrossRefPubMedGoogle Scholar
  20. 20.
    de Jong JS, van Diest PJ, van der Valk P, Baak JP (1998) Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 184:44–52CrossRefPubMedGoogle Scholar
  21. 21.
    Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS (1997) Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94:979–984CrossRefPubMedGoogle Scholar
  22. 22.
    Dias S, Choy M, Alitalo K, Rafii S (2002) Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99:2179–2184CrossRefPubMedGoogle Scholar
  23. 23.
    Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ (2003) Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201:544–554CrossRefPubMedGoogle Scholar
  24. 24.
    Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N, Yanaga K (2006) Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 11:38–43CrossRefPubMedGoogle Scholar
  25. 25.
    Witte D, Thomas A, Ali N, Carlson N, Younes M (2002) Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 22:1463–1466PubMedGoogle Scholar
  26. 26.
    Marchio S, Primo L, Pagano M, Palestro G, Albini A, Veikkola T, Cascone I, Alitalo K, Bussolino F (1999) Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi’s sarcoma cells. J Biol Chem 274:27617–27622CrossRefPubMedGoogle Scholar
  27. 27.
    Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104:603–610CrossRefPubMedGoogle Scholar
  28. 28.
    Timoshenko AV, Rastogi S, Lala PK (2007) Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 97:1090–1098CrossRefPubMedGoogle Scholar
  29. 29.
    Di MJ, Wang WX, Lan MY (2008) The Expression and Significance of VEGF-C and VEGFR-3 in Gastric Carcinoma. Chin J Clin Gastroenterol 20:150–152Google Scholar
  30. 30.
    Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, Aikou T (2004) Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10:8413–8420CrossRefPubMedGoogle Scholar
  31. 31.
    Homma S, Hasumura S, Nagamori S, Kameda H (1988) Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell 1:95–97PubMedGoogle Scholar
  32. 32.
    Shimada H, Endo I, Togo S, Nakano A, Izumi T, Nakagawara G (1997) The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer 79:892–899CrossRefPubMedGoogle Scholar
  33. 33.
    Choi JH, Oh YH, Park YW, Baik HK, Lee YY, Kim IS (2008) Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci 23:592–597CrossRefPubMedGoogle Scholar
  34. 34.
    Thelen A, Scholz A, Benckert C, von Marschall Z, Schroder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S (2008) VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer 122:2471–2481CrossRefPubMedGoogle Scholar
  35. 35.
    Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K (2001) Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 93:662–666CrossRefPubMedGoogle Scholar
  36. 36.
    Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, Tschachler E (1999) Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells. Lab Invest 79:243–251PubMedGoogle Scholar
  37. 37.
    Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M (2003) Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25:464–474CrossRefPubMedGoogle Scholar
  38. 38.
    Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, Chayama K (2002) Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 38:1413–1419CrossRefPubMedGoogle Scholar
  39. 39.
    Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883–1886CrossRefPubMedGoogle Scholar
  40. 40.
    Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K (2004) Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46:11–19CrossRefPubMedGoogle Scholar
  41. 41.
    Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME (2009) Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. Prostate 69:982–990CrossRefPubMedGoogle Scholar
  42. 42.
    He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:819–825PubMedGoogle Scholar
  43. 43.
    Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, Takanashi Y, Kitamura H (2004) Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 45:325–337CrossRefPubMedGoogle Scholar
  44. 44.
    Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K (2005) Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901–6909CrossRefPubMedGoogle Scholar
  45. 45.
    Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkila P, Joensuu H, Alitalo K (2008) VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13:554–556CrossRefPubMedGoogle Scholar
  46. 46.
    Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC, Hung MC, Kuo ML (2008) Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 13:557–560CrossRefPubMedGoogle Scholar
  47. 47.
    Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K, Sueishi K (2009) Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol 175:1709–1721CrossRefPubMedGoogle Scholar
  48. 48.
    Kurenova EV, Hunt DL, He D, Fu AD, Massoll NA, Golubovskaya VM, Garces CA, Cance WG (2009) Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle 8:2266–2280PubMedGoogle Scholar
  49. 49.
    Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511–521CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Yanling Chen
    • 1
    • 2
  • Lei Jiang
    • 1
    • 2
  • Feifei She
    • 3
  • Nanhong Tang
    • 1
  • Xiaoqian Wang
    • 1
  • Xiujin Li
    • 1
  • Shenghua Han
    • 2
  • Jinhai Zhu
    • 2
  1. 1.Hepatobiliary Surgery Institute, Union HospitalFujian Medical UniversityFuzhouChina
  2. 2.Department of Hepatobiliary Surgery, Union HospitalFujian Medical UniversityFuzhouChina
  3. 3.Research Center for Molecular Medicine, The Key Laboratory of Infection and Oncology of Universities in Fujian ProvinceFujian Medical UniversityFuzhouChina

Personalised recommendations